Annual Report 2007 3-24-08.pdf - Moffitt Cancer Center

Annual Report/2007
MOFFITT IN MOTION
The Momentum Quickens… Cures Are Realized… Lives Are Restored
2007 Annual Report 1

CONTENTS
3 2007 Year In Review
6 The Melanoma Story
20 Financial Highlights
22 Leadership Listing
Left to right: Perioperative staff members Brigitte Blevins, R.N.,
Susan Schroder, R.N., Imogene Gardner, R.N., and Donald Fill, CRNA,
are among those who play an active role in patient care.
ON THE COVER
Florida resident Jacqueline “Jackie”
Smith returns to New York to pursue
her dream of earning a Ph.D. A
melanoma survivor, Ms. Smith was
treated at Moffitt Cancer Center.
Photo by Dick Dickinson

Can You Feel The Momentum?
2007 YEAR IN REVIEW
Senator Connie Mack
At the H. Lee Moffitt Cancer Center
& Research Institute things are always
in perpetual motion –– and the past year
was exceptionally so. With our momentum
growing, we are making advances at
a lightning-fast pace as we move forward
with our mission in view –– to contribute
to the prevention and cure of cancer.
In this annual report you will read
about a newly established Comprehensive
Melanoma Research Center, made
possible by a generous gift of $20.4
million from Donald A. Adam. Mr. Adam,
a melanoma survivor himself, is chairman
and chief executive officer of
American Momentum Bank, headquartered
in Tampa. You will also read about
the physicians, researchers, and staff
members who are pursuing the dream
of curing cancer –– some of them are
newly recruited; many others have been
with the Cancer Center since it opened
its doors more than 20 years ago.
With Florida ranking second in
the nation in the number of melanoma
cases, it is appropriate that the Donald
A. Adam Comprehensive Melanoma
Research Center be located here in this
state –– and beyond that –– at Moffitt
Cancer Center, where more than 1,500
new melanoma patients are treated
each year. This innovative approach to
integrated melanoma research and
treatment aims to promote the translation
of basic science discoveries to clinical
trials, ultimately leading to better treatments
and cures.
Everything we do at Moffitt centers
around our patients. In this report, you
will read about Jacqueline Smith, whose
progress toward earning her Ph.D. was
temporarily suspended when she received
a diagnosis of melanoma. Despite a
negative prognosis, she persevered,
coming to Moffitt for surgery and followup
treatment. Ms. Smith, now cancer-free,
says her life is back on track, and she is
returning to school to pursue her educational
goals. In addition, you will meet
Grace Bernard of Port St. Lucie who
underwent surgery and a noninvasive
technique called isolated limb infusion
to treat melanoma.
Additional comprehensive research
centers are being developed here at the
Cancer Center, starting with lung cancer
and drug discovery –– two areas that
have received some substantial external
funding. We anticipate that as these
research initiatives mature, other such
comprehensive research centers will be
developed at Moffitt to target specific
forms of cancer.
Highlights of Moffitt’s continued
growth and progress this year
include:
• Esteban Celis, M.D., Ph.D., received the
2007 Aging & Cancer Pilot Research
award for his project titled “Age-
Related Genetic and Immunological
Profiles in Breast Cancer.” This project
is part of a five-year Aging & Cancer
grant, awarded by the National Institutes
of Health to Paul Jacobsen, Ph.D.,
leader of Moffitt’s Health Outcomes &
Behavior Program. The pilot research
award includes several subprojects, led
by the following principal investigators:
Timothy Yeatman, M.D. (“Age-Related
Gene Expression Patterns in Breast
Cancer”); Julie Djeu, Ph.D. (“NK Cells
and Breast Cancer: Impact of Aging”)
and Dr. Celis (“CTL-Inducing Peptide
Vaccines: Impact of Aging”).
• The National Cancer Institute (NCI)
awarded Moffitt an $8.95 million program
project grant for drug discovery
under the leadership of Saïd Sebti, Ph.D.
The project’s long-term goal is the
discovery of novel drugs for the treatment
of cancer based on disrupting
aberrant signal transductions circuits
in human tumors. The five-year grant
covers five projects and three shared
Moffitt patient Jackie
Smith is happy that her
life is moving forward
after successfully
battling melanoma.
Above right, from left:
James J. Mulé, Ph.D.,
Donald A. Adam,
Jeffrey S. Weber, M.D.,
Ph.D., and Vernon K.
Sondak, M.D.
2007 Annual Report 3

facilities. Researchers will work to
develop drugs that will help break
down the hallmarks of cancer that
include: uncontrolled cell division,
resistance to tumor apoptosis, invasion
and metastasis, as well as angiogenesis,
the formation of new blood
vessels, especially those that supply
oxygen and nutrients to cancerous
tissue. Each of the five projects is led
by two researchers: a biologist and
a chemist, including Jiandong Chen,
Ph.D., Mark McLaughlin, Ph.D.,
Srikumar Chellappan, Ph.D., Nicholas
Lawrence, Ph.D., Dr. Sebti, Hong-Gang
Wang, Ph.D., and Jerry Wu, Ph.D.
• Moffitt researchers led by Moffitt
Research Institute Director Thomas
Sellers, Ph.D., received a $7.3 million
NCI grant to study ovarian cancer
genes. The goal of the five-year grant
is to examine DNA and risk factor
data and identify women who are
at risk for ovarian cancer based on
their genetic makeup. The result may
reveal novel targets for prevention
and treatment. Dr. Sellers says the
novel approach overcomes the limitation
of previous strategies and may
reveal targets never before imagined
to be important.
• A research team led by Dmitry
Gabrilovich, M.D., Ph.D., reported a
discovery that helps explain why
experimental anticancer vaccines are
not as effective as they need to be.
The researchers demonstrated how a
tumor can block the immune response
against itself, and their findings were
reported in the July 2007 issue of
the scientific journal Nature Medicine.
The Jan. 11, 2008, issue of Science
highlighted Dr. Gabrilovich’s contribution
to the field.
• A team of physicians and scientists
led by Nagi Kumar, Ph.D., R.D., F.A.D.A.,
received a $3.6 million grant over five
years from the NCI to study the effect
of Polyphenon E, which is developed
from green tea, in preventing progression
of early stages of prostate cancer.
Their long-term goal is to develop
safe, nontoxic nutrients that can be
consumed safely over long periods
that will prevent progression of prostate
cancer in men at high risk or with earlystage
disease, according to Dr. Kumar.
The Moffitt team includes Drs. Julio
Pow-Sang, Wade Sexton, Loveleen
Kang, Saïd Sebti, Aslamuzzaman
Kazi, Kathleen Egan, Michael Schell,
Gwendolyn Quinn and Karen
Besterman-Dahan, M.A., R.D. Other
participating institutions include the
University of Chicago, Jefferson Medical
Center in Philadelphia and the James
A. Haley Veterans’ Hospital in Tampa.
• A team of Moffitt physicians played
a key role in the recently published
American College of Chest Physicians
“Evidence-based Guidelines on the
Diagnosis and Management of Lung
Cancer.” Moffitt’s Chief Medical Officer
W. Michael Alberts, M.D., M.B.A.,
chaired the effort and authored the
Introduction and the Executive
Summary. Other Moffitt physicians
who authored sections or served as
chapter editors are Gerold Bepler,
M.D., Ph.D., Jhanelle Gray, M.D., Lary
Robinson, M.D., George Simon, M.D.,
and Craig Stevens, M.D., Ph.D.
• The geographic proximity and large
Hispanic populations in Florida and
Puerto Rico have driven the formation
of an academic partnership between
the Ponce School of Medicine and
Moffitt Cancer Center. The partnership
is funded by NCI through its Minority
Institution/Cancer Center Partnership
program and is led by Moffitt’s W. Jack
Pledger, Ph.D., and Ponce’s José A.
Torres Ruiz, Ph.D. Projects underway
include basic science research studies,
a cancer training and education program,
community outreach programs
From left, M2Gen President and
Chief Scientific Officer Timothy
Yeatman, M.D., Moffitt President/CEO
and Center Director William Dalton,
Ph.D., M.D., Hillsborough County
Administrator Pat Bean, Hillsborough
Board of County Commissioners
Chairman Ken Hagan, Moffitt board
member Stephen Meyers, Moffitt
patient Ron Giovannelli, M2Gen COO
Rick Garrison, and Hillsborough
County Commissioners Rose Ferlita
and Jim Norman broke ground on
the M2Gen site.
4 MOFFITT CANCER CENTER

This is the ninth consecutive year that Moffitt has
been included in the newsmagazine’s cancer list and
the first year for the ear, nose and throat list.
A rendering of the building that will house M2Gen.
for cancer prevention and control,
and a tissue procurement core.
• Moffitt was recognized by U.S. News
& World Report’s “America’s Best
Hospitals for Cancer” and “America’s
Best Hospitals for Ear, Nose and Throat”
lists at #16 and #42, respectively.
This is the ninth consecutive year that
Moffitt has been included in the newsmagazine’s
cancer list and the first
year for the ear, nose and throat list.
• This year has been one of growth and
expanding outreach for our Board of
Advisors under the outstanding leadership
of Chairman Sam Donaldson.
Membership increased to 29 with the
addition of former U.S. Senator Bob
Graham, Tampa Bay Rays principal
owner Stuart Sternberg, and Kim
Casiano, president of Puerto Ricobased
Casiano Communications.
Advisors hosted fund-raising events;
videotaped public service announcements;
published ongoing articles
in AAA’s electronic newsletter
and Going Places magazine;
partnered with Moffitt and its
affiliated hospitals for Mole
Patrols and educational events in
Pensacola, Tallahassee, Heathrow,
and Fort Lauderdale; communicated
with state and federal leaders
on Moffitt’s behalf; and offered
advice and insight on a variety of
issues important to Moffitt. Thanks to
their efforts, Moffitt’s message now
reaches beyond Florida to millions of
people around the world. More exciting
activities are planned in 2008, including
Mole Patrols at various Major
League Baseball spring training sites in
Florida and a cancer education event
in Ponce, Puerto Rico.
In our previous annual report, we
noted that as 2006 neared its end, the
Cancer Center announced a new partnership
between Moffitt and Merck & Co.,
Inc. This alliance centers around the goal
of developing personalized treatments
for cancer patients. We also reported
that Moffitt’s spin-off company –– Moffitt
Genetics Corporation d/b/a M2Gen –– has
inspired state and local governments to
invest in our new partnership, as these
initiatives contribute to Florida’s burgeoning
biotech efforts. M2Gen, Moffitt’s
for-profit company, was established to
implement a major research collaboration
between Moffitt Cancer Center
and Merck.
Another exciting “first” took place
as 2007 drew to a close. November 14,
2007, marked the M2Gen groundbreaking.
M2Gen will use molecular technology to
develop personalized cancer treatment
for patients. Researchers will collect
tumor tissues from thousands of patients
across Florida and identify the biological
markers unique to each tumor. Analyzing
patients’ responses to specific treatments
will lead to more individualized treatment
featuring rapid improvement and fewer
side effects. As this annual report
goes to press, the Moffitt Total Cancer
Care/M2Gen initiative has generated
more than 5,200 tumor samples eligible
for gene profiling. Patients, community
providers, industry, government and many
others will be involved in improving cancer
care through M2Gen. Incentives for the
development of M2Gen came from a
variety of sources including the investment
of $20 million along with a donation of
25 acres of land by Hillsborough County,
$15 million from the State of Florida,
and $800,000 along with a donation of
5 acres of land from the City of Tampa.
Construction for the building that will
house M2Gen started as this annual
report went to press and is scheduled
for completion within one year.
The race intensifies. The momentum
at Moffitt Cancer Center is real –– can you
feel it? With more than 3,800 Moffitt
physicians, researchers and staff pursuing
the dream of preventing and curing
cancer, it’s no surprise that we’re seeing
it materialize. And reaching that goal
seems more attainable every day. I believe
that curing cancer is no longer a question
of “if” but rather “when.” Will today be
the day?
Senator Connie Mack
Chairman
2007 Annual Report 5

Momentum Against Melanoma Is Building
Cancer can change your life. Just ask Ph.D. student Jacqueline Smith, 29, of Orlando who was
diagnosed with melanoma after she had started the first semester of her doctoral program at
Syracuse University.
“I had a lump in my groin and all the doctors who looked at it said it was nothing to worry about,”
she recalls.
But, with the persistence of the graduate student she was, she sought more information and finally
had a biopsy. The diagnosis –– melanoma. Worse, Ms. Smith was told that it would be a miracle if she lived
beyond five years. Not only did her Ph.D. work come to a screeching halt, but for a time so did her life.
“I went home to Orlando,” she says. “My doctor there told me I needed to go to Moffitt Cancer
Center. I’d never heard of Moffitt.” So, she contacted Moffitt and, although she didn’t know it then,
started the wheels of her life back into motion.
“I remember as they were taking my information over the phone,
someone asked, ‘and you are a white female?’ Wrong, I said. I’m African-
American.”
“It is a common misperception that people with darker skin don’t get
skin cancer, but that simply is not true,” says Vernon Sondak, M.D., who
performed Ms. Smith’s surgery. Dr. Sondak leads Moffitt’s Cutaneous
Oncology Program.
Ms. Smith’s life now is back on track. At the beginning of 2008 she
returned to New York where she is channeling her energy back into her
educational goals as she pursues her Ph.D. in Sociology.
Jackie Smith’s life is back on track after
surgery and treatment for melanoma.
What is melanoma and how is it different from other cancers?
Melanoma is a skin cancer that
begins in the cells that produce skin pigment,
“the melanocytes.” These cells produce
melanin to protect skin from the
harmful ultraviolet rays of the sun.
However, UV rays can damage the DNA,
or genetic material in skin cells. The
genetic damage can cause uncontrolled
cell growth and cell division that can
develop into melanoma. Unlike many
other skin cancers, melanoma cells can
spread quickly to vital organs.
Still, if caught early, melanoma is
almost always curable, notes Dr. Sondak.
“But if it gets just a little bit thicker or
if a few cells break free and get into the
lymph nodes, it can turn into being one
of the most deadly and refractory (treatment-resistant)
diseases that we treat.”
Risk factors for melanoma include
a family history of melanoma, abnormal
or numerous moles on the skin, fair
complexion, frequent high intensity sun
exposure, and a history of blistering sunburns.
Using tanning booths has also
recently been clearly linked to melanoma
development. And although light-skinned
people are more prone to burning and sun
damage that could lead to skin cancer
such as melanoma, people with darker
skin also can be affected.
Melanoma, now the fifth most common
malignancy in the U.S., is difficult
to treat in part because of the inherent
biology of melanocytes, the cells that
lead to melanoma. Cancer treatments
such as chemotherapy and radiation
therapy cause DNA damage, and the
hope is that cancer cells will be more sensitive
to this type of damage than normal
cells. But melanocytes are designed to
protect our bodies from DNA damage
caused by ultraviolet radiation. So it is
not surprising that the treatments that
cause DNA damage and that work in
other forms of cancer are of little value
in treating melanoma.
On the other hand, melanoma is
unique in that the body’s immune system
tends to recognize this cancer better
than it does other human tumors. That
is why physician-scientists believe that
immunotherapy may be more effective
in treating melanoma. Yet even though
the immune system “sees” melanoma, in
most cases the tumor continues to grow.
Gene Therapy Boosts
Immune System
Pumping the interleukin-12 gene
directly into melanoma tumors is the aim
of a novel gene therapy technique called
“electroporation” used by Adil Daud, M.D.,
director of the Moffitt Clinical Research
Network, and Richard Heller, Ph.D., of the
University of South Florida College of
Medicine.
“In this technique, a small electric
shock opens a tumor’s pores long enough
to insert a gene,” explains Dr. Daud.
A hand-held device delivers six short
electric pulses after the gene is injected
into the tumor. This treatment renders
the tumor more permeable to the interleukin-12
gene, allowing the tumor to be
clearly “visualized” by the immune system.
Twenty-four patients were treated
in the first-ever trial with electroporation
gene therapy at Moffitt. Three of the
24 patients had a complete remission
of all melanoma tumors, even those distant
from the treatment site, indicating
that the immune system was activated.
A larger trial to confirm these exciting
results is planned.
6 MOFFITT CANCER CENTER

Comprehensive Melanoma Research
Center Is Launched
With a gift of $20.4 million, melanoma survivor and CEO of American Momentum Bank in Tampa,
Donald A. Adam has opened doors to a brighter future for people like Ms. Smith, their families, and those
who in the future will battle melanoma, a deadly form of skin cancer that is on the rise.
“Cases of melanoma are increasing at a record rate in the U.S.,” says William S. Dalton, Ph.D., M.D.,
president and CEO of Moffitt. “Mr. Adam’s gift will allow us to continue building the necessary momentum
to respond aggressively to this disease through the creation of the Comprehensive Melanoma
Research Center (CMRC) where new ideas in the fight against melanoma will, hopefully, lead to a cure.”
Building on the research and translational work already being carried out by Moffitt’s Cutaneous
Oncology Program, Mr. Adam’s gift will fund five years of intensive melanoma research in what has been
named the Donald A. Adam Comprehensive Melanoma Research Center.
“The CMRC will not be a free-standing building but, rather, both a network of collaboration and
an environment in which research and clinical goals, crossing many Moffitt departments and research
groups, will create a new synergy for moving forward in a more aggressive way,” explains Dr. Dalton.
Donald A. Adam
“Mr. Adam’s gift will
allow us to continue
building the necessary
momentum to respond
aggressively to this
disease through
the creation of the
Comprehensive
Melanoma Research
Center (CMRC) where
new ideas in the fight
against melanoma
will, hopefully, lead
to a cure.”
2007 Annual Report 7

Strong Clinical Program Helps Spur Melanoma Research
With the link between sun exposure and melanoma firmly established for some time, the statistics
surrounding the rise in melanoma cases, most dramatically in all of the “Sunbelt” states, are startling.
It’s estimated that seven percent of the approximately 60,000 melanomas diagnosed in the U.S. each
year are diagnosed in Florida. Florida is second only to California in the number of new melanoma cases
in the U.S. annually. And with the incidence of most other forms of cancer actually declining slightly in
Florida, melanoma is the only major form of cancer whose incidence rate continues to rise in the state,
according to the state’s most recent records.
With roughly 1,500 melanoma patients being treated at Moffitt annually, the clinical infrastructure
has helped to lay the groundwork to increase research and treatment efforts, which now are being
strengthened and expanded through the CMRC.
Of course, statistics tell only part of the story. For Mr. Adam, the disease also is personal. The philanthropist
survived this form of skin cancer himself nearly 20 years ago. Many others dear to him have not
been as fortunate. “Few people know that melanoma claims more years of a person’s life than almost
any other form of cancer in the United States,” Mr. Adam said. “With this gift, I am confident that Moffitt
will take research and treatment of melanoma to the next level.”
According to Jeffrey Weber, M.D., Ph.D., director of the CMRC, Mr. Adam’s gift will propel melanoma
research toward enhanced and expanded collaboration. “What will set the Donald A. Adam
Comprehensive Melanoma Research Center apart from other research centers will be our strength in
every area –– cell research, surgery, clinical trials and drug development,” says Dr. Weber, who sits on the
National Cancer Institute’s Clinical Oncology Study section as well as the boards of the Melanoma
Research Foundation and the Melanoma Therapeutics Foundation. “The CMRC will have a synergistic
effect because it will be an integrated effort. It will bring translational researchers and clinicians together,
albeit under a metaphorical roof, yet a place where thinking can be inside as well as outside ‘the box.’”
Decades Of Expertise Enlisted In The Fight Against Melanoma
The three top leaders of the CMRC have much in common, sharing a long history of
collaboration while working at various institutions before joining forces at Moffitt. Dr. Weber
has known Dr. Sondak for 18 years and Dr. Mulé for more than 22 years –– for an aggregate
Jackie Smith, left,
relaxes with her mother,
Barbara Smith, before
returning to college
in New York.
of 40 years. And they all are committed to finding cures for melanoma.
”An area of research that I think is most promising is the use of
immune regulatory antibodies. There is a host of new antibodies
in the pipeline.”
~Jeffrey S. Weber, M.D., Ph.D.
Dr. Weber earned his Ph.D. in molecular cell biology from Rockefeller
University (New York) in 1979 and received his M.D. from New York
University in 1980. His experience includes clinical, research and teaching
positions at the University of California, Irvine, and the University
of Southern California where he was chief of oncology and in charge of
therapeutic development at the USC/Norris Comprehensive Cancer Center.
Coming to Moffitt in 2007, Dr. Weber is the head of the Donald A.
Adam Comprehensive Melanoma Research Center and associate chair for medicine in
the Department of Oncologic Sciences.
A specialist in molecular cell biology, Dr. Weber is principal investigator (PI) on
several ongoing studies under the National Institutes of Health (NIH) and the National
Cancer Institute (NCI), including trials in clinical drug development, vaccines, and studies
on autoimmunity and melanoma.
Dr. Weber has published 93 studies and serves as a permanent member of the
Veterans Administration’s clinical oncology study section.
Jeffrey S. Weber, M.D., Ph.D.
8 MOFFITT CANCER CENTER

In addition to Dr. Weber, the leadership team for the CMRC includes James J. Mulé, Ph.D., a worldrenowned
translational scientist and Dr. Sondak, an internationally known melanoma surgeon.
The CMRC will expand on the already vigorous Moffitt melanoma scientific research efforts by hiring
new scientists to study the biology and behavior of the “melanocyte,” the precursor cell to malignant
melanoma. This initiative will lead to establishing even larger tissue and cell line banks. The drug discovery
effort will be accelerated, enhancing and expanding clinical trials programs.
“Our Cutaneous Oncology Program has
developed tremendously over the years and,
happily, is going to continue to develop thanks
to Mr. Adam’s gift,” notes Dr. Sondak. “The
CMRC will greatly enhance and provide new
momentum for our ‘bench to bedside’ research
efforts. Bringing in new people changes and
strengthens the playing field. That is the
essence of synergy.”
For Dr. Mulé, executive vice president
and Michael McGillicuddy Endowed Chair
for Melanoma Research and Treatment, the
collaborative foundation already forged with
Drs. Weber and Sondak over their decades
of working together while at different institutions
will only strengthen with the development
of the CMRC.
Melanoma survivor
Mildred Mederos (center)
and her husband,
George Mederos, meet
with Darcelle Welker,
R.N., in Moffitt’s
Cutaneous Clinic.
“The mission of the CMRC is to make a measurable impact on the
disease. That’s why we see value in combining prevention with research
and treatment.”
~James J. Mulé, Ph.D.
As executive vice president and Michael McGillicuddy Endowed Chair of
Melanoma Research and Treatment, Dr. Mulé is involved in a number of ongoing
NIH and NCI studies as PI and co-PI. Several studies aim at developing treatments
based on immune response and antitumor clinical responses.
Dr. Mulé earned his Ph.D. in tumor immunology and immunopathology from the University
of Washington, Seattle in 1981. He has been at Moffitt since 2003 and serves as executive vice
president of Applied Science and Technology. He is a 2008 nominee for the Institute of Medicine,
National Academy of Sciences.
Before coming to Moffitt, Dr. Mulé was professor, Department of Surgery, at the University
of Michigan Medical Center and director of the Tumor Immunology & Immunotherapy Program
at the University of Michigan Comprehensive Cancer Center.
James J. Mulé, Ph.D.
“The biology of melanoma is very specific to melanocytes that are designed
to protect our bodies from DNA damage caused by ultraviolet radiation.
Melanoma has needed its own cadre of researchers who are willing to think
‘outside the box’ in terms of research.”
~Vernon K. Sondak, M.D.
Dr. Sondak leads the Cutaneous Oncology Program and is director of
Surgical Education at Moffitt. He has authored or coauthored 150 articles and
contributed chapters to 45 books –– and is coeditor of an upcoming book on
translational research in melanoma. Dr. Sondak received his M.D. in 1980 from
Boston University School of Medicine. Until he came to Moffitt in 2004, he was
professor in the University of Michigan’s Department of Surgery. A leader in
studies of surgical treatment for melanoma and other cutaneous malignancies,
Dr. Sondak has also been involved in clinical studies to improve the treatment of soft tissue sarcomas
and desmoid tumors. He serves as chair of the Melanoma Committee of the Southwest Oncology
Group and is involved in the design and conduct of melanoma clinical trials.
Vernon K. Sondak, M.D.
“What will set the
Donald A. Adam
Comprehensive
Melanoma Research
Center apart from
other research
centers will be our
strength in every area ––
cell research, surgery,
clinical trials and
drug development.”
2007 Annual Report 9

Immunotherapy Research May Lead To Cure
“Melanoma is one of the few human tumors to be immunogenic to the immune system,” explains
Dr. Mulé, who has sat on the National Cancer Institute’s Board of Scientific Counselors. “In other words,
the human immune system ‘sees’ melanoma better than it sees other human tumors, yet allows the
tumor to continue to grow. That’s why we believe that immunotherapy may hold a key to curing
melanoma. That’s also why we need a broad approach and additional researchers to better understand
the genetics and biology of melanoma.”
New investigators recruited by
the CMRC will supplement the existing
drug development and immunology
programs and will augment the current
clinical strength in medicine, surgery,
dermatology and pathology.
“Moffitt has the distinction of
being a free-standing, consensus institution
as opposed to being a top-down,
autocratic institution,” says Dr. Weber.
“The climate here already fosters innovation
and collaboration. Under the
CMRC umbrella, increased resources
will help us to do better what we do
already, and do more of it.”
The Comprehensive Melanoma Research Center is stimulating
the translation of scientific findings to the clinic. Here Moffitt
researcher Hiroshi Komine, M.D., views melanoma cells.
Research Vision Intensifies As Momentum Builds
In the fight against melanoma,
the path from “bench to bedside” often
starts with a small, first step –– a
research idea that matures into a new
chemical compound that appears to
have activity against melanoma cells.
Along that path, patients volunteer for
clinical trials hoping to benefit from new
treatments and also hoping to benefit
those who come after them. Scientists
working in laboratories and the people
who come to Moffitt for treatment are
allies as each puts his or her hopes
and hard work into bringing new treatments
to those who need it. Working
together, we are creating momentum
against this challenging disease. Goals
of the CMRC are to develop:
• Successful strategies leading to
new drugs and immune therapies
for melanoma.
• New screening assays for
melanoma.
• New diagnostic tests for melanoma.
• New insights into the genetic
and biochemical events that lead
to melanoma.
• New molecular targets for
treatment.
• A more complete understanding
of the genetic abnormalities
characteristic of melanoma.
• New drugs.
• New and better uses for current
drugs.
Minimally Invasive Procedure
Uses Current Drugs
One example of a better way to use
an existing drug in the treatment of
melanoma is the work of Jonathan Zager,
M.D. A surgical oncologist specializing in
melanoma and sarcoma and a recent
arrival at Moffitt, Dr. Zager brought with
him a minimally invasive technique called
“isolated limb infusion,” or ILI, to treat
recurrent melanoma or melanoma
metastases in the extremities.
The procedure uses a heated
chemotherapy delivered directly to the
site of the affected extremity by means
of a thin catheter inserted into a main
artery of a patient’s leg. The patient is
under a general anesthesia during the
30-minute treatment.
Afterward,
the patient stays
in the hospital
for a few days’
observation and
then goes home,
returning later for
a positron-emission
tomography Grace Bernard
(PET) scan.
Dr. Zager reports that complications
are less than with other, more invasive
techniques to treat recurrent melanoma
in the extremities, and that overall
patients have shown up to a 70 percent
response rate.
Grace Bernard, 83, of Port St. Lucie,
Florida, who was diagnosed with
melanoma in her thumb, then her wrist
and arm, made the trip to Tampa to see
Dr. Zager. The great-grandmother of two,
who had several surgeries on her arm
prior to undergoing ILI, says acquaintances
ask her why she goes all the way
to Tampa to be treated instead of being
treated closer to home.
10 MOFFITT CANCER CENTER

“...the human immune system ‘sees’ melanoma better than
it sees other human tumors, yet allows the tumor to continue
to grow. That’s why we believe that immunotherapy may
Dendritic cells with the nucleus stained blue.
Moffitt investigators have developed and
are studying the effectiveness of dendritic
cell-based vaccines in treating melanoma
and other cancers.
hold a key to curing melanoma.”
“Because Moffitt and Dr. Zager saved
my life,” Ms. Bernard tells them. “It was
spreading and that treatment stopped it.
I think he’s wonderful.”
According to Dr. Zager, Ms. Bernard
has had a “complete response.”
The procedure, which can be repeated
if necessary, allows large doses of
anticancer drugs to be delivered directly
to the affected limb without affecting the
rest of the body. And although currently
limited to treating melanoma confined
only to one arm or leg, Dr. Zager and
others at Moffitt are hoping to expand
this type of treatment to hard-to-treat
melanoma metastases in the liver as well.
James Ryland chats with
Carla Erario, R.N., and
Jonathan Zager, M.D.,
before undergoing a
minimally invasive
isolated limb infusion
procedure to treat
melanoma.
2007 Annual Report 11

Center Links Genetics Research,
Clinical Trials To Develop Better Treatments
Tissue samples from
cancerous tumors, including
melanoma, are collected
from consenting patients
and undergo gene profiling.
This is part of the push
to develop new therapies
that are personalized
for each patient. Slava
Petrovsky, right, passes
a tumor tissue specimen
to Harrison Borno.
Having the CMRC will increase the number of melanoma patients seeking treatment at Moffitt.
Not only will patients gain the advantage of being treated at one of the nation’s flagship institutions,
but also they will have increased opportunities to enroll in clinical trials where they can access the latest
treatments.
Having a larger melanoma patient base will allow Moffitt researchers to conduct more clinical trials,
which may help current patients and ultimately will benefit the melanoma patients of tomorrow.
“By studying larger numbers of melanoma patient samples in great molecular detail, we will greatly
improve our diagnostics,” notes Dr. Mulé. “This will facilitate our selection of patients for clinical trials
based on the molecular characterization of their disease and help us identify new therapeutic agents.”
In turn, a “personalized” approach to treating melanoma that includes genetic components will
focus the attention of researchers –– even those doing basic science –– on new approaches to treatment.
“The CMRC will also allow us to develop new screening assays and new diagnostic tests,” promises
Dr. Sondak. “Each new insight into the genetic and biochemical events that accompany the transition
from normal melanocytes to invasive melanoma will lead to new targets for treatment.”
By increasing the number of clinical trials within the existing Cutaneous Oncology Program, Moffitt
researchers and clinicians also will have access to a greater number of federal and industry protocols
and collaborations that may lead to new treatments.
Led by Dr. Sondak, Moffitt investigators already participate in the Southwest Oncology Group
(SWOG), a network of more than 5,000 physician-researchers at 550 institutions, including 17 of the
12 MOFFITT CANCER CENTER

National Cancer Institute’s 61 designated cancer centers. SWOG annually enrolls 3,000 to 5,000
cancer patients in clinical trials. Dr. Sondak has been involved in the design and conduct of major
national clinical trials aimed at new treatments for melanoma.
Another collaboration that will be enhanced by the CMRC is Moffitt’s ongoing work with the
Translational Genomics Institute (TGen) of Phoenix, Arizona.
“TGen is a group that specializes in sequencing cancer genomes,” explains Dr. Weber. “Some
of our resources will be devoted to working with TGen on melanoma.”
Jeffrey Trent, Ph.D., president and scientific director of TGen, started the nonprofit organization
to study the genetics of cancer to better diagnose, treat and cure cancer through “translational
genomics,” which employs many of the advances rising from the Human Genome Project.
According to Dr. Weber, Moffitt will provide up to 450 melanoma specimens and conduct
some of the research here, while TGen and other collaborators will contribute specialized expertise
to a large melanoma genomics project aimed at collecting genetic information on a large number
of primary and metastatic melanomas and building a database that can be linked with clinical
information.
“The project fits nicely with our efforts with Total Cancer Care,” says Dr. Dalton. In less than
two years, Moffitt surgeons and pathologists have captured over 200 melanoma tumor samples
from patients who have consented. Obtaining melanoma tumor tissue is notoriously difficult ––
especially from the relatively small primary tumors, which have often been removed by a dermatologist
or family doctor before referral to a research center like Moffitt. It requires an active
collaboration between the melanoma surgeons and the dermatopathologists at Moffitt to ensure
that the specimens needed for research are obtained without hindering the ability to analyze
patients’ specimens for all needed pathologic information.
Barbara Smith, left, is
happy that her daughter,
Jackie, is now cancerfree
and moving forward
with her life.
Activating Community Awareness: Mole Patrol Intensifies
Push Toward Early Detection And Prevention
In the 12 years of its existence,
Moffitt’s Mole Patrol has
traveled through the state of
Florida, screening thousands
of people for skin abnormalities
and educating the public
on skin cancer prevention and
early detection.
“To screen people for skin
cancer, the Mole Patrol works
with Moffitt affiliates,” says
Dr. Sondak. “In addition to providing
early detection, we also
The Mole Patrol team at MacDill Air Force Base.
educate people about skin cancer
and encourage the use of
sunscreen and other ways to protect the skin from the damaging ultraviolet rays of the sun.”
The Mole Patrol has covered numerous special events, even having shown up at the
“waterfront.” On Veterans Day, 2007, the Mole Patrol sailed from the Port of Tampa to
Egmont Key and back on board the SS American Victory, a vintage World War II ship. On
the day-long cruise, Mole Patrol specialists screened veterans, their families, the ship’s crew
and other passengers.
“Thick melanomas are rising significantly in men over age 60,” says Jane Messina, M.D.,
director of the Mole Patrol. “Men are least likely to have their skin checked regularly, so it is
particularly important to screen older men, especially veterans.”
The aim for screening is, of course, to catch melanoma and other skin cancers at the very
beginning stages to increase the likelihood of successful treatments.
“It’s generally true that if we catch melanoma early on, the outlook is very, very good,”
says Dr. Sondak.
2007 Annual Report 13

Research Does Not Sacrifice Patient Care
Moffitt dermatopathologist Jane L. Messina, M.D., is in the forefront of the very front lines in the
battle against melanoma. “In fact, she and her colleagues in Pathology at Moffitt have played a big role
in a major effort to move melanoma research forward while doing all possible to help assure a successful
outcome for current patients,” says Dr. Sondak.
“Over the years melanoma research has been limited by
the concern that if a patient’s tumor specimen is sent to the
research laboratory without being examined by the pathologist,
some aspect of their medical care could be negatively
affected,” Dr. Sondak notes. “At Moffitt, Dr. Messina makes
sure that doesn’t happen. She makes sure that the melanoma
patients donating tissue to the tumor bank are safeguarded.”
After patients consent to donate tissue to the Moffitt
tissue bank for research purposes, the small sample must be
frozen and quarantined until the specimen is reviewed and
approved by Dr. Messina before it is released for research.
“We have very close coordination between tissue procurement,
pathology assistants and the pathologist,” explains
Dr. Messina. “If the tissue is released for research, it is also
examined by a pathologist to make sure it accurately represents
the patient’s tumor.”
Dermatopathologist Jane Messina, M.D.,
evaluates tissue samples.
Investigator Awards Drive Melanoma Research Forward
Several Moffitt
researchers already
are concentrating
on discovering more
about melanoma.
The first grant
awards through the
CMRC have been
presented to several
investigators for
their innovative
work.
Dmitry Gabrilovich,
M.D., Ph.D.
Harnessing
The Power Of
Immunotherapy
Dmitry Gabrilovich,
M.D., Ph.D., an immunologist
and Moffitt’s Scientist
of the Year for 2006, has
been examining melanoma
tumor mechanisms and
the potential of immunotherapy
for combating
melanoma. “Because the
treatment is genetically tailored to an individual’s
tumor, immunotherapy of melanoma is very
attractive,” says Dr. Gabrilovich. “The further development
of immunotherapy is a focus of Moffitt’s
2010 Strategic Goals to discover, translate and
deliver personalized cancer care.”
Much of Dr. Gabrilovich’s work on this project
is aimed at better understanding and demonstrating
the factors that limit the effectiveness of
immunotherapy, including what factors prevent
cytotoxic T cells from recognizing and eliminating
tumors. His work on the role of myeloid-derived
suppressor cells in sustaining tumors is highlighted
in an article published in the Jan. 11, 2008,
issue of Science.
Defining Resistance
To Therapy
Prakash Chinnaiyan,
M.D., radiation oncologist,
is examining the therapeutic
resistance of
melanoma brain metastases.
“Limited therapeutic
options are available
for these patients,”
Prakash Chinnaiyan, M.D.
explains Dr. Chinnaiyan.
“Our studies are focused
on developing novel model systems to recapitulate
underlying resistance demonstrated in
melanoma brain metastases. Our hypothesis
is that tumor stem cells have the plasticity to
metastasize to the brain and may contribute to
both chemotherapy and radiation resistance.”
Therefore, tumor stem cells are currently being
isolated from brain metastases specimens, and
response rates to traditional therapies are being
defined to provide a framework to test novel
approaches designed to overcome intrinsic
resistance.
14 MOFFITT CANCER CENTER

“Personalized Medicine” Ultimately Will
Become Reality For Cancer Patients
Total Cancer Care (TCC) is a growing statewide enterprise and
research project initiated by Moffitt. TCC promises to deliver “personalized
medicine” –– a new approach to treatment of melanoma and
all forms of cancer made possible by advances in molecular biology
and genetics. The result is therapies that will be tailored to fit each
person’s unique genetic profile.
Diagnosis and treatment of melanoma and other cancers by a
personalized medicine approach means that the right treatment can
be matched to the right patient through “genetic signatures.” Because
each tumor has a specific genetic makeup, clinicians can use tumor
“gene expression profiles” to predict the drugs to which each patient’s
tumors may best respond.
Matching the patient’s genetic signature
and specific “biomarkers” in the tumor to a
specific drug has the advantage of allowing
the patient to leap over treatments that will
likely be less effective than the genetically
and molecularly matched treatment.
Harrison Borno prepares a tumor sample that will be
used in research. More than 5,200 tumor tissue samples
have been collected (and are eligible for gene profiling)
from patients at Moffitt and its network of affiliates.
Diagnosis and treatment of melanoma and other cancers by
a personalized medicine approach means that the right treatment
can be matched to the right patient through “genetic signatures.”
Unraveling Risk
Factors For
Melanoma
Dana E. Rollison,
Ph.D., an epidemiologist in
Moffitt’s Risk Assessment
Detection and Intervention
Program, conducts a
variety of studies, several
of which are aimed at
Dana E. Rollison, Ph.D.
unraveling independent
risk factors for different
types of skin cancer, including melanoma.
“Exposure to ultraviolet radiation from the
sun, fair skin and family history are clear risk
factors for melanoma,” says Dr. Rollison. “We
are studying additional genetic factors that may
be related to abnormal moles, or nevi. Atypical
moles can be a marker for identifying people
at high risk for melanoma.”
In a current study, Dr. Rollison and colleagues
are trying to establish a clearer association
between abnormal nevi and melanoma by
examining the relationship between telomere
length in blood cells and abnormal nevi count.
Telomeres consist of repeated DNA sequences
at the ends of chromosomes, and telomere
lengths have been associated with increased
risks of a variety of cancers.
“Telomere lengths have also been correlated
with higher numbers of atypical moles, which is
of particular relevance to melanoma,” explains
Dr. Rollison. Her research raises the possibility of
finding a genetic “common denominator” that
might eventually explain why some moles turn
into melanoma.
Pushing To
Boost Tumor
Suppression
Srikumar Chellappan,
Ph.D., a member of the
Drug Discovery Program
and Moffitt’s Scientist
of the Year for 2007,
is working toward a
better understanding of
Srikumar Chellappan, Ph.D.
metastatic melanoma by
examining a biochemical
“cascade” in melanoma tumor growth and the
effect of a small molecule called RRD-251 that
could inhibit the process and promote tumor
suppression. “Our studies have the potential
to identify novel agents to combat melanoma,”
says Dr. Chellappan. “If we can use RRD-251 to
prevent the growth, progression and metastasis
of melanomas, new and effective treatments
may emerge.”
2007 Annual Report 15

Keeping The Momentum Going:
Future Plans Are Aggressive
“It will be exciting to watch as the Donald A. Adam Comprehensive Melanoma Research Center
translates scientific discoveries to the clinic –– all with the aim of beating melanoma,” says Dr. Dalton.
“And we also are committed to the prevention and cure of all forms of cancer. To that end, we are
working to take them down one at a time.”
Moffitt Cancer Center is planning other research centers that will focus on a specific disease or
scientific effort. Now in development are centers devoted to translational research in lung cancer, led
by Gerold Bepler, M.D., Ph.D., leader of Moffitt’s Thoracic Oncology Program, and in drug discovery, led
by Saïd Sebti, Ph.D., leader of the Drug Discovery Program.
“Launching these initiatives to overtake and, one day in the future, eliminate cancer is very aggressive
and expensive and will require the collaboration and financial support of many different people and
various resources,” says Dr. Dalton. “We are seeking support from various organizations and individuals.”
Along with Dr. Dalton, Dr. Weber emphasizes that generous donations of varying amounts –– large
and small –– from multiple sources are needed to continue funding the CMRC and to keep the current
research momentum in steady motion forward.
Part of Moffitt’s Total Cancer
Care/M2Gen initiative that
aims to deliver personalized
cancer care, this new “robotic
freezer” (demonstrated by
Celia Sigua) is an automated
tissue sample and storage
retrieval system. It has a
capacity of thousands of
samples that are stored at
-80 degrees Centigrade
(-112 degrees Fahrenheit).
In studying these samples,
scientists can assimilate
extensive data on
treatment effectiveness.
16 MOFFITT CANCER CENTER

”It will be exciting to watch as the Donald A. Adam Comprehensive
Melanoma Research Center translates scientific discoveries to the clinic ––
all with the aim of beating melanoma.”
William S. Dalton,
Ph.D., M.D.
“The need to fund such an ambitious endeavor with so much potential to contribute to the prevention
and cure of cancer –– specifically melanoma –– will be ongoing,” says Dr. Weber. “As the efforts at the
Moffitt CMRC continue to help find cures for melanoma, we hope that the scientific findings gleaned
from melanoma research may have value in research involving other cancers, even other diseases.”
All the efforts –– the basic scientific research, the clinical trials themselves, combined with genetic
analyses –– everything involved in these translational research initiatives –– are designed with the goal
to yield better treatments and personalized therapies for patients with cancer.
Jackie Smith (right) on
her way back to college.
She says that Dr. Sondak
and the Moffitt staff
encouraged her to
persevere, highlighting
the importance of
moving forward
and staying active
and involved.
2007 Annual Report 17

Cutaneous Team Builds The Program
While the new CMRC will move translational research in the
area of melanoma to the next level of excellence, the Cutaneous
Oncology Program team, led by Vernon Sondak, M.D., surgical
oncologist, has long been at the forefront of melanoma research
and treatment initiatives. Many of the program members have
been with Moffitt since the Cancer Center
opened its doors more than 20 years ago.
Here we will meet some of the many individuals
who helped establish and move the
Cutaneous Oncology Program forward.
Ronald C. DeConti, M.D.
Neil A. Fenske, M.D.
L. Frank Glass, M.D.
Ronald C. DeConti, M.D., medical
oncologist, was Moffitt’s Physician of the
Year in 2000 and also serves as chief of
Moffitt Hospital’s Medical Service and hospital
medical director. Dr. DeConti specializes
in melanoma, Merkel cell cancer and head
and neck cancers with a focus on clinical
trials. He received his M.D. from the Yale
University School of Medicine in 1959.
Neil A. Fenske, M.D., a dermatologist,
is chair of the Department of Dermatology
and Cutaneous Surgery at the University
of South Florida. He also plays an integral
role in the Cutaneous Oncology Program
at Moffitt, where he sees patients and performs
surgeries. He received his M.D. from
the St. Louis University School of Medicine
in 1973. He is board-certified in dermatology
with a subspecialty of dermatopathology.
Besides melanoma, his research interests
are in other forms of skin cancer, aging
skin and psoriasis.
“The growth of the Cutaneous Oncology Program has been awe-inspiring,”
says Dr. Fenske. “Our work on the role of lymphatic mapping and the sentinel
node biopsy has changed the way melanoma is managed. It’s been a real
privilege to be part of the effort to provide our patients with the highest level
of care available.”
L. Frank Glass, M.D., received his M.D. from Louisiana State University
in 1985. A board-certified dermatologist, Dr. Glass has research interests in
melanoma and other skin cancers. His subspecialty is dermatopathology.
“One of the biggest changes in the Cutaneous Oncology Program has been
growth, in terms of an ever-increasing number of patients and more specialists
working within the program,” says Dr. Glass.
He performs up-front surveillance and follow-up for patients who have had
melanoma and are at high risk. “With careful follow-up, further melanomas in
these patients will be caught at an early stage.” Because of his strong interest
in cutaneous T-cell lymphoma, Dr. Glass also is a member of Moffitt’s Malignant
Hematology Program.
C. Wayne Cruse, M.D.
C. Wayne Cruse, M.D., received his M.D. from the University of Louisville
in 1972. He is board-certified in surgery and plastic surgery. His research interests
are in cutaneous oncology and include melanoma, sarcoma, wounds and reconstruction following surgery.
“I have been associated with the Cutaneous Oncology Program since its initiation,” says Dr. Cruse.
“Since that time, we’ve cared for more melanoma patients than any other institution in Florida and
the southeastern U.S. and have made great progress in early detection, diagnosis and treatment of
melanoma. Much more needs to be accomplished, however.”
18 MOFFITT CANCER CENTER

Like members of all Moffitt Cancer Center’s clinical
programs, Cutaneous Oncology members work as an
interdisciplinary team, focusing on patient care, clinical
research, education and cancer control activities.
Surgical oncologists, medical oncologists, radiation
oncologists, pathologists, dermatologists and
plastic surgeons are among the medical specialists who round out the team.
In addition to Drs. Sondak, DeConti, Fenske, Glass and Cruse, physicians within
the Cutaneous Oncology Program include:
Working as an interdisciplinary
team, each member of the
Cutaneous Oncology Program
plays a key role in beating
skin cancers.
Claudia G. Berman, M.D.
Basil S. Cherpelis, M.D.
Adil I. Daud, M.D.
Mary Lien, M.D.
Tomasz Marzec, M.D.
Jane L. Messina, M.D.
Gerard C. Mosiello, M.D.
David Smith, Jr., M.D.
Margaret M. Szabunio, M.D.
Andrea “Andy” Trotti, III, M.D.
Jeffrey Weber, M.D., Ph.D.
Jonathan S. Zager, M.D.
Diagnostic radiology
Dermatology/Mohs
micrographic surgery
Medical oncology
Dermatology
Dermatopathology/cytopathology/
anatomic and clinical pathology
Dermatopathology
Plastic and reconstructive surgery
Plastic surgery
Diagnostic radiology
Radiation oncology
Medical oncology/
immunology
Surgical oncology
2007 Annual Report 19

2007
FINANCIALS Moffitt Cancer Center
CONSOLIDATED BALANCE SHEET
June 30, 2007 June 30, 2006
ASSETS
Current Assets
Cash & Cash Equivalents $12,691,966 $4,423,794
Current Portion of Assets Limited as to Use 15,161,302 14,350,699
Current Portion of Pledges Receivable 14,786,876 5,709,975
A/R Less Allowance for Uncollectibles 62,933,571 59,102,618
Other Current Assets 21,901,518 25,422,793
Total Current Assets $127,475,233 $109,009,879
Assets Limited as to Use $110,423,808 $116,119,736
Pledges Receivable 9,055,100 4,356,295
Property, Plant & Equipment 269,652,340 236,977,716
Construction in Progress 17,765,631 19,765,997
Other Assets 1,554,638 2,252,501
$408,451,517 $379,472,245
Total Assets $535,926,750 $488,482,124
LIABILITIES AND NET ASSETS
Current Liabilities $84,261,820 $80,314,673
Other Liabilities 3,569,089 3,589,607
Long-Term Debt 101,333,490 114,980,247
Net Assets 346,762,351 289,597,597
Total Liabilities and Net Assets $535,926,750 $488,482,124
CONSOLIDATED STATEMENT OF REVENUE AND EXPENSES
June 30, 2007 June 30, 2006
REVENUE
Net Patient Service Revenues $361,256,072 $326,841,188
Other Revenues 63,756,926 54,016,111
Net Assets Released from Restrictions
and Used for Operating Expenses 19,306,358 17,220,433
Total Unrestricted Revenue
and Other Support $444,319,356 $398,077,732
EXPENSES
Operating Expenses $415,156,873 $357,247,945
Depreciation and Amortization 30,700,610 29,341,442
Interest 4,926,870 5,298,709
Provision for Bad Debts 5,601,699 5,093,606
Total Expenses $456,386,052 $396,981,702
(Loss) Income from Operations $(12,066,696) $1,096,030
Non-operating Gains, Net 6,572,257 6,108,733
(Deficiency) Excess of Revenues and
Gains over Expenses and Losses $(5,494,439) $7,204,763
20 MOFFITT CANCER CENTER

Gerald and Kathleen Flynn converse before Mr. Flynn’s surgery
while Julia Cramer, SRNA, works in the preoperative area.
Kathleen Fill, CRNA, center, and Julia Cramer, SRNA,
help prepare Gerald Flynn before surgery.
MOFFITT PATIENT ORIGIN FY 2007
29.3% Hillsborough
County
PATIENT CARE
Out of State 5.8%
9.1% Pasco
County
ANNUAL TOTALS FY 07 FY 06
Admissions 7,261 6,492
Outpatient Visits 264,533 250,560
Patient Days 45,377 42,715
Average Length of Stay 6.4 6.5
Other Florida 31.7%
9.5% Pinellas
County
4.3% Polk County
2.8% Hernando County
3.8% Manatee County
3.7% Sarasota County
10 MOST FREQUENT CANCER SITES: 2006 *
2007 PAYER MIX
Skin ** 11.41%
11.25% Lung and Bronchus
Medicare 32%
Breast 11.96%
8.53% Prostate
7% Medicaid
5.36% Colorectal
3% Other
1% Private Pay
1% Commercial
Other Sites 33.77%
4.16% Non-Hodgkin
Lymphoma
3.60% Leukemia
3.43% Kidney
3.38% Bladder
3.15% Pancreas
HMO/PPO 56%
* Includes analytic and non-analytic cases for accession year 2006
There were a total of 6,563 analytic and non-analytic cases for accession year 2006
** Excludes basal cell and squamous cell carcinoma
Yearly Data supplied to Public Relations and Marketing for updating the Annual Report
2007 Annual Report 21

LEADERSHIP
LISTING Moffitt Cancer Center
BOARD OF DIRECTORS
H. Lee Moffitt Cancer Center
& Research Institute, Inc.
Senator Connie Mack, Chair
Timothy J. Adams, Vice Chair
Donald D. Buchanan
The Honorable Carl Carpenter, Jr.
Theodore J. Couch, Sr.
Judy L. Genshaft, Ph.D.
The Honorable John A. Grant
The Honorable James T. Hargrett
Monsignor Laurence Higgins
Benjamin H. Hill, III, Esquire
Beth A. Houghton
Renu Khator, Ph.D.
Rhea F. Law, Esquire
The Honorable H. Lee Moffitt
Philip Orsino
Robert Rothman
Jack Spangler
H. Lee Moffitt Cancer Center
& Research Institute Hospital, Inc.
Beth A. Houghton, Chair
Manuel Garcia, Vice Chair
W. Michael Alberts, M.D., M.B.A.
Karen A. Arnold
The Honorable Thomas E. Baynes
Joseph Caballero
Julie Y. Djeu, Ph.D.
Harvey Greenberg, M.D., M.B.A.
Dwayne Hawkins
Ronald A. Hurst
Stephen K. Klasko, M.D., M.B.A.
The Honorable Gwen Miller
The Honorable H. Lee Moffitt
The Honorable Mark A. Pizzo
Mary Anne Reilly
George William Tinsley, Sr.
H. Lee Moffitt Cancer Center & Research
Institute Foundation, Inc.
Benjamin H. Hill, III, Esquire, Chair
Edward C. Droste, Vice Chair/Chair Elect
Alfred S. Austin
Suzette Berkman
Thilo Best
G. Robert Blanchard, Jr.
Joseph Caballero
The Honorable Monterey Campbell
Ronald J. Campbell
Michael Conroy, C.P.A.
Joe B. Cox, Esquire
Eileen Sena Curd
Rebecca Walter Dunn
Cecelia (Celia) D. Ferman
George A. Franklin
Richard Gonzmart
The Honorable Dick A. Greco
Timm Harmon
Peter T. Kirkwood, Esquire
John Kynes
Steven Matzkin, D.D.S.
Col. John W. Mitchell, Sr.
The Honorable H. Lee Moffitt
Carol Morsani
Pamela Muma
William F. Poe, Jr.
Barbara Ryals
Patrick Sobers
Jack Spangler
Donald W. Wallace
Julie Wooley
Andrea McCray, Ph.D., prepares to
incubate dendritic cells that will be
used in scientific research.
H. Lee Moffitt Cancer Center & Research
Institute Lifetime Cancer Screening Center, Inc.
Timothy J. Adams, Chair
Rolfe Arnhym
Donald D. Buchanan
Jennifer Capeheart-Meningall, Ed.D.
Gwen Mitchell
The Honorable H. Lee Moffitt
Robert J. Perez, D.D.S.
The Honorable Mark A. Pizzo
The Honorable Donald C. Sullivan, M.D.
John J. Yodzis
Moffitt Technologies Corporation
Stephen A. Meyers, Chair
Theodore J. Couch, Sr.
William S. Dalton, Ph.D., M.D.
Steven Gillis, Ph.D.
Ken Moch
The Honorable H. Lee Moffitt
Linda Powers
Charles Resnick
Robert Rothman
Moffitt Genetics Corporation d/b/a M2Gen
William S. Dalton, Ph.D, M.D., Chair
Donald D. Buchanan
John A. Kolosky, C.P.A., M.B.A.
James J. Mulé, Ph.D.
Nicolas C. Porter, M.Ed.
Thomas A. Sellers, Ph.D., M.P.H.
BOARD OF ADVISORS
Sam Donaldson, Chairman
ABC News Correspondent
Clifford L. Alexander, Jr.
President, Alexander & Associates, Inc.;
Former Secretary of the Army
Gary Bettman
Commissioner, National Hockey League
Francis T. Borkowski, Ph.D.
Former Chancellor, Appalachian State University;
Former President, University of South Florida
Shelley Broader
President and Chief Executive Officer,
Sweetbay Supermarket
Kimberly Casiano
President, Casiano Communications, Inc.
David S. Chernow
Chief Executive Officer, OnCURE Medical Corp.
Robin Cook, M.D.
Physician and Author
Senator Bob Dole
Special Counsel, Alston & Bird;
Former U.S. Senator
Newt Gingrich
Founder, Center for Health Transformation;
Former Speaker, U.S. House of Representatives
Senator Bob Graham
Former U.S. Senator;
Former Governor of Florida
Bob Griese
ABC Sports College Football Analyst;
Member, Pro Football Hall of Fame
Brian Griese
Tampa Bay Buccaneers;
Founder & President, Judith Ann Griese Foundation
Robert Ingram
Vice Chairman of Pharmaceuticals, GlaxoSmithKline
Sidney Kimmel
Founder and Chairman, Jones Apparel Group;
Chairman, Sidney Kimmel Foundation
Richard Klausner, M.D.
Managing Partner, The Column Group;
Former Director, National Cancer Institute
G. Timothy Laney
Senior Executive Vice President for Business Services,
Regions Financial Corporation
Joseph R. Lee
Retired Chairman, Darden Restaurants, Inc.
LaSalle D. Leffall, Jr., M.D.
Charles R. Drew Professor of Surgery,
Howard University College of Medicine
Governor Bob Martinez
Senior Policy Advisor, Holland & Knight, LLP;
Former Governor of Florida
Marty Nealon
Divisional President, Kenneth Cole Productions
Tom O’Brien
President and CEO, AAA Auto Club South
Arnold Palmer
Professional Golfer and Businessman
Steven A. Raymund
Chairman of the Board, Tech Data Corporation
Cokie Roberts
ABC News Analyst
H. Norman Schwarzkopf
General, USA, Retired
Mel Sembler
Chairman of the Board, The Sembler Company;
U.S. Ambassador, Retired
Stuart L. Sternberg
Principal Owner, Tampa Bay Rays Baseball, Ltd.
Susan Story
President and CEO, Gulf Power Company
22 MOFFITT CANCER CENTER

INTERNAL LEADERSHIP
President/Chief Executive Officer
& Center Director
William S. Dalton, Ph.D., M.D.
Deputy Center Director
W. Jack Pledger, Ph.D.
Director, Moffitt Research Institute
Thomas A. Sellers, Ph.D., M.P.H.
Executive Vice President and
Associate Center Directors
W. Jack Pledger, Ph.D.
Basic Science
Director, National Functional Genomics Center
Thomas A. Sellers, Ph.D., M.P.H.
Cancer Prevention & Control
Daniel M. Sullivan, M.D.
Clinical Investigations
Executive Vice Presidents
David de la Parte
General Counsel
John A. Kolosky, C.P.A., M.B.A.
Chief Operating Officer
James J. Mulé, Ph.D.
Applied Science & Technology
Nicolas C. Porter, M.Ed.
Institutional Advancement and Corporate Relations
S. Clifford Schold, Jr., M.D.
Physician-In-Chief
Chief Academic Officer
Chair, Department of Oncologic Sciences
Timothy J. Yeatman, M.D.
Translational Research
President & Chief Scientific Officer, M2Gen
Director, Total Cancer Care (TCC) for
Personalized Medicine
Senior Vice President
Braulio Vicente, Jr.
Hospital/Clinics Chief Operating Officer
Vice Presidents
W. Michael Alberts, M.D., M.B.A.
Medical Affairs/Chief Medical Officer
Michael Benedict, Ph.D.
Clinical Investigations
Janene Culumber
Chief Financial Officer
Larry Feder
Foundation
Anne Goff, M.Ed.
Research Operations/CCSG Administrator
Brenda Gordon
Clinic & Ancillary Services
B. Lee Green, Ph.D.
Office of Institutional Diversity
Kelly Hall
Faculty Affairs
Dean Head
Facilities Management & Construction
Edward Martinez
Information Technology/Chief Information Officer
Mary Beth Reardon, R.N., M.S.
Patient Care Services/Chief Nursing Officer
Yvette Tremonti
Human Resources
Jamie Wilson
Government Relations
Research Program Leaders
Julie Y. Djeu, Ph.D.
Scott Antonia, M.D., Ph.D.
Immunology Program
Anna Giuliano, Ph.D.
Risk Assessment, Detection & Intervention Program
Paul B. Jacobsen, Ph.D.
Health Outcomes & Behavior Program
Director, Total Cancer Care (TCC) for
Health Outcomes
Saïd Sebti, Ph.D.
Drug Discovery Program
Edward Seto, Ph.D.
Molecular Oncology Program
Daniel M. Sullivan, M.D.
Experimental Therapeutics Program
Director, Comprehensive Thoracic
Research Center
Gerold Bepler, M.D., Ph.D.
Director, Comprehensive Drug Discovery
Research Center
Saïd Sebti, Ph.D.
Director, Donald A. Adam Comprehensive
Melanoma Research Center
Jeffrey S. Weber, M.D., Ph.D.
Clinical Program Leaders & Chiefs of Service
Claudio Anasetti, M.D.
Blood and Marrow Transplantation Program
Lodovico Balducci, M.D.
Senior Adult Oncology Program
Gerold Bepler, M.D., Ph.D.
Thoracic Oncology Program
Claudia G. Berman, M.D.
Interim, Radiology Service
Steven Brem, M.D.
Neuro-Oncology Program
W. Bradford Carter, M.D.
Endocrine Tumor Program
Paul Chervenick, M.D.
TGH Adult Oncology Service
Domenico Coppola, M.D.
Anatomic Pathology Service
Ronald C. DeConti, M.D.
Medicine Service
Hospital Medical Director
Richard A. Gross, M.D.
Internal and Hospital Medicine Program
Paul B. Jacobsen, Ph.D.
Psychosocial & Palliative Care Program
Johnathan M. Lancaster, M.D., Ph.D.
Gynecologic Oncology Program
Christine Laronga, M.D.
Interim, Don & Erika Wallace Comprehensive
Breast Program
G. Douglas Letson, M.D.
Sarcoma Program
Alan F. List, M.D.
Malignant Hematology Program
Deputy Physician-In-Chief
Mokenge P. Malafa, M.D.
Gastrointestinal Oncology Program
Thomas V. McCaffrey, M.D., Ph.D.
Head & Neck Oncology Program
Lynn C. Moscinski, M.D.
Hematopathology and Laboratory Medicine Service
Julio M. Pow-Sang, M.D.
Genitourinary Oncology Program
Surgical Service
Vernon K. Sondak, M.D.
Cutaneous Oncology Program
Craig W. Stevens, M.D., Ph.D.
Radiation Oncology Service
David Thrush, M.D.
Anesthesiology Service
Medical Staff Officers
Eric Sommers, M.D.
President
Hector Vila, Jr., M.D.
President-Elect
Scott Antonia, M.D., Ph.D.
Secretary/Treasurer
Melissa Alsina, M.D.
Member-At-Large
Barbara Centeno, M.D.
Member-At-Large
Chris Garrett, M.D.
Member-At-Large
Frank W. Walsh, M.D.
Member-At-Large
Moffitt patient James Ryland, left,
and his son, James Ryland, Jr.
2007 Annual Report 23

FLORIDA IS THE OFFICIAL PLACE OF BUSINESS FOR THE H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE FOUNDATION, INC. A COPY OF THE OFFICIAL REGISTRATION AND FINANCIAL INFORMATION MAY BE OBTAINED FROM THE DIVISION OF CONSUMER
SERVICES BY CALLING 1-800-435-7352 TOLL-FREE WITHIN THE STATE. REGISTRATION DOES NOT IMPLY ENDORSEMENT, APPROVAL, OR RECOMMENDATION BY THE STATE. FLORIDA DEPARTMENT OF AGRICULTURE & CONSUMER SERVICES REGISTRATION NUMBER
CH-4675. NO PERCENTAGE OF CONTRIBUTIONS ARE RETAINED BY A PROFESSIONAL SOLICITOR, 100% OF ALL DONATIONS ARE RECEIVED BY THE FOUNDATION.
H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, AN NCI COMPREHENSIVE CANCER CENTER – TAMPA, FL. 1-888-MOFFITT
This 2007 annual report for the H. Lee Moffitt Cancer Center & Research
Institute is published by the Department of Public Relations & Marketing,
Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612-9416.
Additional copies may be obtained by calling 813-745-1355. If you would
like to be removed from the mailing list, please call 813-745-1355.
Director, Marketing & Strategic Communications: Melissa Mackey
Managing Editor: Cathy Clark
Contributing Writers: Cathy Clark, Randolph Fillmore
Design: JAG Communications, Inc.
Photography: Dick Dickinson
www.MOFFITT.org
A National Cancer Institute
Comprehensive Cancer Center
At the University of South Florida
H. Lee Moffitt Cancer Center
& Research Institute Inc
12902 Magnolia Drive
Tampa, FL 33612-9416
NON-PROFIT ORG
US POSTAGE
PAID
TAMPA FL
PERMIT NO 2849
MILES FOR MOFFITT
Continues To Run Strong:
5K And One-Mile Event
Benefits Cancer Research
Miles for Moffitt at USF will be known as
Bank of St. Petersburg Miles for Moffitt at USF
(the University of South Florida) for the next
three years. “We are pleased to make Bank of
St. Petersburg part of our race name,” says Karen
Dalton, the Miles for Moffitt founder and wife
of William S. Dalton, Ph.D., M.D., president and CEO
of Moffitt Cancer Center. “As the title supporter,
Bank of St. Petersburg is demonstrating how
strongly the organization feels about advancing
Moffitt’s mission: ‘to contribute to the prevention
and cure of cancer.’” Mrs. Dalton is chairing the
event, which is entering its third year.
MILESFOR
Moffitt
at the University of South Florida
Mrs. Dalton created Miles for Moffitt in
2006 to help celebrate the anniversary of Moffitt
Cancer Center’s 20 years in the community and
as an opportunity for Tampa Bay area residents
to support Moffitt in a fun, affordable event that
has a health benefit.
The 5K and one-mile walk/run event will
take place on Saturday, May 10, 2008, starting
at 7:30 a.m. at the USF Sun Dome. The event
includes kids’ events, Health Fair sponsored by
Moffitt and USF College of Public Health, Survivor
Celebration of Life and an awards presentation.
New this year is a $2,500 purse to be divided
among the top three race finishers.
Since its founding two years ago, with SunTrust
Bank as the first title sponsor, Miles for Moffitt
doubled its number of participants to 2,400 and
has raised more than $125,000 for cancer research
at Moffitt. Race sponsorship chairperson is Priscilla
Mack, wife of Moffitt Board Chairman Senator
Connie Mack.
Thanks to the support provided by the Bank of
St. Petersburg and other event sponsors, 100 percent
of participants’ entry fees benefit Moffitt’s cancer
research. Media sponsors include News Channel 8,
The Tampa Tribune, Tampa Bay’s Q105 and WQYK.
Race registration is available at
www.milesformoffitt.com or you can call
813-745-1346.